Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients.
The effect of bezafibrate (BZF) on plasma fibrinogen levels has been studied in 62 patients with atherosclerotic vasculopathy and hyperfibrinogenemia (643 +/- 15 (SEM) mg/dl). In a preliminary study, 15-30 days of BZF therapy (400-600 mg/day) normalized fibrinogen values in 16 subjects were compared to 16 controls. The effect was rapid and dose-dependent, and discontinuation in 6 patients who could not complete the study was followed by a rebound increase. A controlled study with 400 mg/day in the other 24 patients for 15 days showed that BZF lowered fibrinogen, PF4, blood filterability and platelet aggregating thresholds to the normal range. BTG and FpA decreased significantly compared to the placebo group (12 and 12 patients randomly distributed) without any variation in potentially biassing hematologic values (WBC, PLTS, Ht, lipids and plasma glucose). BZF may be of value in chronic treatment of hyperfibrinogenemia in atherosclerotic patients with a view to improving the haemorheologic pattern and, hence, reducing activation of the coagulation pathway.
Niort
G
G
Istituto di Medicina Interna, Università di Torino, Italy.
Bulgarelli
A
A
Cassader
M
M
Pagano
G
G
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000097:blood* / Q000188:drug therapy; D001629:Bezafibrate / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000097:blood* / Q000188:drug therapy; D001792:Blood Platelets / Q000502:physiology; D005340:Fibrinogen / Q000032:analysis*; D005344:Fibrinopeptide A / Q000097:blood; D006801:Humans; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D011897:Random Allocation; D012212:Rheology
D005344:Fibrinopeptide A; D005340:Fibrinogen; D001629:Bezafibrate